Recurrent transverse myelitis following neurobrucellosis: Immunologic features and beneficial response to immunosuppression

Journal of NeuroVirology

Volumn 11, Issue 2, 2005, Pages 225-231

  Krishnan, Chitra ^a   Kaplin, Adam I ^a   Graber, Jerome S ^a   Darman, Jessica S ^a   Kerr, Douglas A ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; IL 6; Immunosuppression; Neurobrucella; Plasma exchange; Recurrent; Transverse myelitis

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE CHEMOTACTIC FACTOR; MEPREDNISONE;

AGED; ANTIBODY TITER; ARTICLE; BRAIN BIOPSY; BRAIN INFECTION; BRUCELLA MELITENSIS; BRUCELLOSIS; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; QUADRIPLEGIA; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; BRUCELLOSIS; CHEMOKINE CCL2; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MYELITIS, TRANSVERSE; RECURRENCE; SPINAL CORD; TREATMENT OUTCOME;

BRUCELLA;

EID: 20744431909     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280590922801     Document Type: Article

References (16)

1. Al Sous MW, Bohlega S, Al Kawi MZ, Alwatban J, McLean DR (2004). Neurobrucellosis: clinical and neuroimaging correlation. AJNR Am J Neuroradiol 25: 395-401.
2. de Seze J, Stojkovic T, Breteau G, Lucas C, Michon-Pasturel U, Gauvrit JY, Hachulla E, Mounier-Vehier F, Pruvo JP, Leys D, Destee A, Hatron PY, Vermersch P (2001). Acute myelopathies: clinical, laboratory and outcome profiles in 79 cases. Brain 124: 1509-1521.
3. Dornand J, Gross A, Lafont V, Liautard J, Oliaro J, Liautard JP (2002). The innate immune response against Brucella in humans. Vet Microbiol 90: 383-394.
4. Gadient RA, Otten UH (1997). Interleukin-6 (IL-6) - a molecule with both beneficial and destructive potentials. Prog Neurobiol 52: 379-390.
5. Gruol DL, Nelson TE (1997). Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15: 307-339.
6. Kerr DA, Ayetey H (2002). Immunopathogenesis of acute transverse myelitis. Curr Opin Neurol 15: 339-347.
7. Kim KK (2003). Idiopathic recurrent transverse myelitis. Arch Neurol 60: 1290-1294.
8. Kochar DK, Agarwal N, Jain N, Sharma BV, Rastogi A, Meena CB (2000). Clinical profile of neurobrucellosis - a report on 12 cases from Bikaner (north-west India). J Assoc Physicians India 48: 376-380.
9. Koussa S, Chemaly R (2003). Neurobrucellosis presenting with diffuse cerebral white matter lesions. Eur Neurol 50: 121-123.
10. Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA (2004). Transverse Myelitis: pathogenesis, diagnosis and treatment. Front Biosci 9: 1483-1499.
11. Olson TS, Ley K (2002). Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 283: R7-R28.
12. Pandit L, Rao S (1996). Recurrent myelitis. J Neurol Neurosurg Psychiatry 60: 336-338.
13. Pascual J, Combarros O, Polo JM, Berciano J (1988). Localized CNS brucellosis: report of 7 cases. Acta Neurol Scand 78: 282-289.
14. Ransohoff RM, Howe CL, Rodriguez M (2002). Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends Immunol 23: 512-516.
15. Seidel G, Pardo CA, Newman-Toker D, Olivi A, Eberhart CG (2003). Neurobrucellosis presenting as leukoencephalopathy: the role of cytotoxic T lymphocytes. Arch Pathol Lab Med 127: e374-e377.
16. Yu X, Kennedy RH, and Liu SJ (2003). JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem 278: 16304-16309.